DorsaVi (ASX:DVL) V6.5 Upgrade Pushes Intelligence Onto the Sensor

Upgrades FDA-Cleared Sensors, No Device Replacement Needed

DorsaVi has today announced its V6.5 Omni Sensor Intelligence upgrade, which is a firmware update that does not require any hardware replacement. It is specifically aimed at the company’s existing FDA-cleared wearable motion sensor platform. This is not a new device, but a software upgrade that can be pushed out to sensors already being used by clients.

At the moment, the sensor mainly collects data and sends it to an edge device or cloud server where the analysis is done. With V6.5, the sensor will begin performing part of that analysis itself directly on the chip inside the wearable. That means less data movement, lower latency, and lower operating cost.

The bigger point is that DorsaVi is not waiting for ReRAM to be fully ready before improving the intelligence of its platform. It is already upgrading the capability of its existing sensor base today, which gives the company a more immediate way to show commercial progress.

Why “Neuromorphic-Ready” Is the Critical Phrase

Standard sensor firmware is built to collect data and send that raw information to external servers for processing. A neuromorphic architecture changes that model completely. Instead of moving everything off the device, it processes data in an event-driven way using spike-based functions that work more like neurons and synapses in the brain. DorsaVi is now building upgraded firmware to support that new network and data architecture.

At the same time, DorsaVi is advancing its ReRAM technology toward 22nm. While 22nm is not the most advanced node globally, it would still be a major step for the company because it should allow for more memory capacity, faster performance, and lower power consumption.

What DorsaVi is doing now is making sure the firmware is ready to support that hardware when it arrives. That silicon is expected to eventually sit inside the Ultra Edge platform, so getting the software layer ready early matters.

Without that sequencing, DorsaVi would risk facing a software development delay on top of a hardware development delay once the 22nm chips mature.

Who Benefits and How

Select Medical Network is already working with DorsaVi and has 1,900 sites across the US, with more than 100 currently using DorsaVi’s sensors. V6.5 should help reduce the lag between movement capture and clinical feedback during patient assessments.

Importantly, the network does not need to replace or pay for new hardware to access that upgrade.

Why Europe’s Regulatory Direction Matters Here

The EU AI Act is the most significant AI regulatory framework being rolled out globally, and it carries a clear bias toward on-device, validated inference in medical and autonomous settings. Cloud-dependent systems, where patient data is sent to remote servers for processing, are facing greater scrutiny under both the AI Act and existing GDPR rules.

V6.5’s shift toward on-sensor processing is directly aligned with that regulatory direction. This is not accidental. DorsaVi explicitly highlighted that point in the announcement. The SEROMA study also gives the company an established European clinical presence at a time when these standards are taking shape, which could become a meaningful first-mover advantage as it looks toward future EU expansion and regulatory pathways.

The Investors Takeaway for DVL

For investors, this is not a revenue event. But for those following the company closely, we see it as a strategic step. DorsaVi is laying the firmware foundations needed to support the next technology upgrade and preparing the platform for its move toward 22nm.

That matters because it allows the company to start building, testing, and refining the software layer early, which should help reduce execution risk and improve the product as the hardware roadmap advances.